Clinical Trial Update: Efficacy of the Combination of Nivolumab and Ipilimumab as a Treatment in Patients With Sarcoma of Rare Subtype [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating nivolumab plus ipilimumab for sarcoma of rare subtypes; results not yet available.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sarcoma

Drugs mentioned

• ipilimumab (ipilimumab)
• nivolumab (nivolumab)

Snippet

Sponsor: Centre Leon Berard | Conditions: Sarcoma | Phase 3 | Status: UNKNOWN